Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.

Ketul R ChaudharyYupu DengColin M SuenMohamad TahaThomas H PetersenShirley H J MeiDuncan J Stewart

Published in: British journal of pharmacology (2018)

Treprostinil exerts therapeutic benefits in PAH through decreased vascular resistance and improved cardiac structure and function; however, treprostinil treatment does not have direct impact vascular remodelling.

Keyphrases

pulmonary arterial hypertension
pulmonary artery
pulmonary hypertension
left ventricular
early onset
endothelial cells
heart failure
combination therapy
coronary artery
polycyclic aromatic hydrocarbons
replacement therapy
atrial fibrillation
drug induced